HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.

@article{Carr2001HIVPI,
  title={HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.},
  author={Andrew Carr and Jeff D Hudson and John Chuah and Simon A Mallal and Matthew V. Law and Jennifer Hoy and Nicholas Doong and Martyn French and Don Smith and David A. Cooper},
  journal={AIDS},
  year={2001},
  volume={15 14},
  pages={1811-22}
}
BACKGROUND Lipodystrophy, dyslipidaemia and insulin resistance often complicate protease inhibitor-containing antiretroviral therapy. The aims of this study were to determine if these are reversible with continued HIV suppression following protease inhibitor substitution. METHODS Eighty-one HIV protease inhibitor recipients (78 male; mean antiretroviral therapy, 55 months) with predominant peripheral lipoatrophy, HIV RNA < 400 copies/ml plasma for at least the preceding 6 months, and no prior… CONTINUE READING
38 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

Similar Papers

Loading similar papers…